drugset / Trial / NCT00527423

Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD

NCT00527423

Phase 2 Completed 157 enrolled Regeneron Pharmaceuticals Bayer · collab
NaSingle-groupSingle-blindTreatment

Summary

Rollover study for subjects in prior VEGF Trap-Eye Phase I and II studies. Primary objective is to assess long-term safety and tolerability of continuing intravitreal treatment in subjects with wet age-related macular degeneration.

Timeline

Start
2007-08
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic Intravitreal